SER-109, the investigational oral microbiome therapeutic from Seres, reduced C diff recurrence by 91.3% in at-risk populations.
Today, Seres Therapeutics announced confirmatory results from ECOSPOR IV, the open-label clinical study of their treatment for recurrent Clostridioides difficile (C diff) infection.
The investigational oral microbiome therapeutic, SER-109, was well-tolerated and had a sustained clinical response rate of 91.3% after 8 weeks in a trial population with a history of recurrent C diff infection (rCDI).
“The 91.3% sustained clinical response rate observed at 8 weeks in the overall study population with recurrent CDI, including those with first recurrence, reaffirms the superior efficacy and favorable safety profile previously observed in the pivotal placebo-controlled ECOSPOR III trial,” said Paul Feuerstadt, MD, FACG, AGAF, the lead author of the New England Journal of Medicine-published study. “As a treating physician, I look forward to the potential approval of this meaningful therapeutic option for patients living with this challenging and debilitating disease.”
The US Food and Drug Administration (FDA) previously designated SER-109 as a Breakthrough Therapy and Orphan Drug for the prevention of rCDI. With positive data from the ECOSPOR IV and prior ECOSPOR III trials, Seres has begun a rolling submission of a Biologics License Application (BLA) to the FDA for SER-109.
The FDA requested safety data from at least 300 subjects treated with a commercial dose of SER-109 to confirm its safety. Seres expects the BLA submission to be completed by mid-2022, and if granted priority review of the application, anticipated launching SER-109 in the first half of 2023.
CDI commonly occurs when antibiotics wipe out the healthy bacteria in the gut, allowing the harmful C diff bacteria to flourish. SER-109 contains a consortium of highly purified Firmicutes spores, which normally live in a healthy gut microbiome. The investigational therapeutic is designed to prevent further CDI recurrence by removing unwanted microbes and restoring the disrupted microbiome to a state that resists C diff colonization and growth.
The ECOSPOR IV (NCT03183141) multicenter, randomized, placebo-controlled, open-label study included 2 cohorts of adults with rCDI. Enrolled patients had a clinical profile consistent with those frequently evaluated and treated in clinical practice.
The participants treated with SER-109 had a recurrence rate of 8.7% at 8 weeks, indicating a 91.3% sustained clinical response. At 24 weeks, 13.7% of all subjects treated with SER-109 had a CDI recurrence.
SER-109 was well-tolerated through 24 weeks. The safety profile observed in ECOSPOR IV was consistent with that of its preceding placebo-controlled study, ECOSPOR III. Together, these 2 trials complete the SER-109 phase 3 development program.
“The ECOSPOR IV data confirm the well-tolerated safety profile and clinical benefit observed in the prior ECOSPOR III study,” said Eric Shaff, president and CEO of Seres. “We believe that SER-109 has the potential to fundamentally transform the management of rCDI across all 170000 annual cases in the US and are working closely with Aimmune Therapeutics, a Nestlé Health Science Company, to bring this therapeutic candidate to patients as quickly as possible.”
Seres hopes SER-109 will become a first-in-class, FDA-approved microbiome therapeutic. SER-109 previously achieved the first-ever positive pivotal clinical trial results for a targeted microbiome drug candidate. Seres is also currently developing microbiome therapeutics for ulcerative colitis.
Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.